Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 52.25
(0.0%)
USD 52.25
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 923.56 Million EUR | 8.15% |
| 2022 | 792.26 Million EUR | 22.45% |
| 2021 | 647.02 Million EUR | 13.89% |
| 2020 | 568.09 Million EUR | -1.25% |
| 2019 | 575.26 Million EUR | 12.6% |
| 2018 | 510.91 Million EUR | 2.88% |
| 2017 | 496.63 Million EUR | 9.65% |
| 2016 | 452.92 Million EUR | 5.6% |
| 2015 | 428.92 Million EUR | 0.83% |
| 2014 | 425.38 Million EUR | 5.29% |
| 2013 | 404 Million EUR | 14.71% |
| 2012 | 352.2 Million EUR | 4.02% |
| 2011 | 338.58 Million EUR | 1.59% |
| 2010 | 333.28 Million EUR | -4.69% |
| 2009 | 349.69 Million EUR | 8.36% |
| 2008 | 322.7 Million EUR | 11.05% |
| 2007 | 290.58 Million EUR | 10.14% |
| 2006 | 263.83 Million EUR | -0.19% |
| 2005 | 264.32 Million EUR | 20.91% |
| 2004 | 218.6 Million EUR | 5.73% |
| 2003 | 206.75 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 223.78 Million EUR | -4.97% |
| 2024 Q2 | 236.73 Million EUR | 4.83% |
| 2023 Q4 | 235.48 Million EUR | 13.93% |
| 2023 Q2 | 203.79 Million EUR | -3.36% |
| 2023 Q1 | 210.88 Million EUR | -6.19% |
| 2023 Q3 | 206.69 Million EUR | 1.43% |
| 2023 FY | 856.85 Million EUR | 8.15% |
| 2022 Q3 | 201.31 Million EUR | 0.28% |
| 2022 FY | 792.26 Million EUR | 22.45% |
| 2022 Q1 | 165.4 Million EUR | -8.25% |
| 2022 Q2 | 200.74 Million EUR | 21.37% |
| 2022 Q4 | 224.79 Million EUR | 11.66% |
| 2021 Q1 | 154.86 Million EUR | 2.29% |
| 2021 Q4 | 180.27 Million EUR | 17.39% |
| 2021 Q3 | 153.56 Million EUR | -3.01% |
| 2021 FY | 647.02 Million EUR | 13.89% |
| 2021 Q2 | 158.32 Million EUR | 2.24% |
| 2020 Q4 | 151.4 Million EUR | 13.22% |
| 2020 FY | 568.09 Million EUR | -1.25% |
| 2020 Q1 | 153.15 Million EUR | -3.37% |
| 2020 Q2 | 129.81 Million EUR | -15.24% |
| 2020 Q3 | 133.72 Million EUR | 3.01% |
| 2019 Q3 | 138.52 Million EUR | 0.92% |
| 2019 FY | 575.26 Million EUR | 12.6% |
| 2019 Q4 | 158.5 Million EUR | 14.42% |
| 2019 Q1 | 140.96 Million EUR | 6.25% |
| 2019 Q2 | 137.27 Million EUR | -2.62% |
| 2018 FY | 510.91 Million EUR | 2.88% |
| 2018 Q4 | 132.67 Million EUR | 11.8% |
| 2018 Q3 | 118.67 Million EUR | -4.17% |
| 2018 Q2 | 123.83 Million EUR | -8.76% |
| 2018 Q1 | 135.72 Million EUR | 4.99% |
| 2017 Q1 | 128.92 Million EUR | 8.13% |
| 2017 Q2 | 120.59 Million EUR | -6.46% |
| 2017 Q3 | 117.84 Million EUR | -2.28% |
| 2017 FY | 496.63 Million EUR | 9.65% |
| 2017 Q4 | 129.27 Million EUR | 9.7% |
| 2016 Q4 | 119.23 Million EUR | 13.49% |
| 2016 Q1 | 117.88 Million EUR | 5.98% |
| 2016 Q2 | 110.75 Million EUR | -6.04% |
| 2016 Q3 | 105.05 Million EUR | -5.15% |
| 2016 FY | 452.92 Million EUR | 5.6% |
| 2015 Q4 | 111.22 Million EUR | 13.84% |
| 2015 Q1 | 113.22 Million EUR | 2.84% |
| 2015 Q2 | 106.77 Million EUR | -5.69% |
| 2015 Q3 | 97.69 Million EUR | -8.5% |
| 2015 FY | 428.92 Million EUR | 0.83% |
| 2014 FY | 425.38 Million EUR | 5.29% |
| 2014 Q2 | 103.56 Million EUR | -6.49% |
| 2014 Q4 | 110.09 Million EUR | 9.04% |
| 2014 Q3 | 100.96 Million EUR | -2.51% |
| 2014 Q1 | 110.75 Million EUR | 6.76% |
| 2013 Q4 | 103.74 Million EUR | 11.99% |
| 2013 Q2 | 102.06 Million EUR | -3.31% |
| 2013 Q1 | 105.56 Million EUR | 27.13% |
| 2013 FY | 404 Million EUR | 14.71% |
| 2013 Q3 | 92.63 Million EUR | -9.25% |
| 2012 Q1 | 93.91 Million EUR | 12.21% |
| 2012 Q2 | 88.35 Million EUR | -5.92% |
| 2012 Q3 | 86.89 Million EUR | -1.65% |
| 2012 Q4 | 83.03 Million EUR | -4.44% |
| 2012 FY | 352.2 Million EUR | 4.02% |
| 2011 Q4 | 83.69 Million EUR | 10.76% |
| 2011 FY | 338.58 Million EUR | 1.59% |
| 2011 Q1 | 86.6 Million EUR | -1.58% |
| 2011 Q2 | 92.71 Million EUR | 7.05% |
| 2011 Q3 | 75.56 Million EUR | -18.49% |
| 2010 Q4 | 88 Million EUR | 18.53% |
| 2010 Q2 | 87.96 Million EUR | 5.87% |
| 2010 FY | 333.28 Million EUR | -4.69% |
| 2010 Q3 | 74.24 Million EUR | -15.6% |
| 2010 Q1 | 83.08 Million EUR | -10.07% |
| 2009 FY | 349.69 Million EUR | 8.36% |
| 2009 Q1 | 82.89 Million EUR | 0.0% |
| 2009 Q2 | 92.65 Million EUR | 11.77% |
| 2009 Q4 | 92.38 Million EUR | 12.98% |
| 2009 Q3 | 81.77 Million EUR | -11.74% |
| 2008 FY | 322.7 Million EUR | 11.05% |
| 2007 FY | 290.58 Million EUR | 10.14% |
| 2006 FY | 263.83 Million EUR | -0.19% |
| 2005 FY | 264.32 Million EUR | 20.91% |
| 2004 FY | 218.6 Million EUR | 5.73% |
| 2003 FY | 206.75 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | 96.878% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | 94.59% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | 56.983% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -1712.009% |
| Novartis AG | 24.87 Billion USD | 96.287% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 99.992% |